These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15118072)

  • 1. Targeting targeted therapy.
    Green MR
    N Engl J Med; 2004 May; 350(21):2191-3. PubMed ID: 15118072
    [No Abstract]   [Full Text] [Related]  

  • 2. K-ras mutations in lung cancer: the "mysterious mutation".
    Hirsch FR
    Clin Lung Cancer; 2006 Jul; 8(1):11-2. PubMed ID: 16870039
    [No Abstract]   [Full Text] [Related]  

  • 3. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
    Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
    J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer. A bull's eye for targeted lung cancer therapy.
    Minna JD; Gazdar AF; Sprang SR; Herz J
    Science; 2004 Jun; 304(5676):1458-61. PubMed ID: 15178790
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictors of the response to gefitinib in refractory non-small cell lung cancer.
    Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; Ahn SJ; Baek SM; Park CS; Park CM; Kim YI; Lim SC; Park KO
    Clin Cancer Res; 2005 Mar; 11(6):2244-51. PubMed ID: 15788673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
    Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
    J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutations and sensitivity to gefitinib.
    Rossi G; Marchioni A; Longo L
    N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15376351
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
    Lai RS; Xie L; Shen LS; He YM; Zhu CL
    Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324
    [No Abstract]   [Full Text] [Related]  

  • 9. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
    Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
    J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 11. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
    Sequist LV; Haber DA; Lynch TJ
    Clin Cancer Res; 2005 Aug; 11(16):5668-70. PubMed ID: 16115901
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
    Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
    Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
    Madelaine J; Cadranel J; Zalcman G
    Rev Mal Respir; 2004 Nov; 21(5 Pt 1):881-5. PubMed ID: 15622331
    [No Abstract]   [Full Text] [Related]  

  • 14. Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
    Márquez-Medina D; Gasol-Cudós A; Taberner-Bonastre MT; Samamé Pérez-Vargas JC; Salud-Salvia A; Llombart-Cussac A
    Arch Bronconeumol; 2013 Feb; 49(2):79-81. PubMed ID: 22627040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
    Yang TY; Tsai CR; Chen KC; Hsu KH; Lee HM; Chang GC
    J Clin Oncol; 2011 Jun; 29(16):e468-9. PubMed ID: 21422421
    [No Abstract]   [Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
    Gazdar AF
    Medicine (Baltimore); 2011 May; 90(3):168-170. PubMed ID: 21512415
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.